Exact Sciences Corp
Exact Sciences to Buy Thrive Earlier Detection, Stock Rises
Liquid Biopsy Data Ignites Exact Sciences Stock
What to Know about the Exact Sciences–Genomic Health Deal
Today, Exact Sciences (EXAS) announced a definitive agreement to acquire Genomic Health (GHDX) for close to $2.8 billion.
Why Exact Sciences Surged 12% Today
On January 7, Exact Sciences (EXAS) rose by 11.96% to $73.50 in the pre-market trading session.
Exact Sciences: Why the Stock Price Is Soaring
On August 22, Exact Sciences (EXAS) is trading at a stock price of $62.95, which represents ~25.78% growth from the close of $50.05 on August 21.
What’s Nektar Therapeutics’ Guidance for Fiscal 2018?
For full fiscal 2018, the company expects to register R&D (research and development) expenses of $400 million to $425 million.
Wall Street Is Bullish on Nektar Stock despite Stock Price Slump
Nektar is a development-stage biotechnology company that has a drug pipeline focused on the treatment of cancer, autoimmune diseases, and chronic pain.